Curcumin AntiCancer Studies in Pancreatic Cancer

Area of Science:

• Oncology
• Natural Compounds
• Cancer Therapeutics

Background:

• Pancreatic cancer (PC) is a leading cause of cancer-related mortality worldwide.
• Surgical resection is the only curative option, but limited by late diagnosis.
• Current chemotherapy (gemcitabine plus nab-paclitaxel) has limitations and side effects.

Purpose of the Study:

• To review preclinical and clinical studies on curcumin's efficacy in treating pancreatic cancer.
• To explore curcumin's potential as an alternative therapy for advanced PC.
• To discuss strategies for overcoming curcumin's bioavailability challenges.

Main Methods:

• Review of in vitro studies demonstrating curcumin's cytotoxic effects on PC cell lines (MiaPaCa-2, Panc-1, AsPC-1, BxPC-3).
• Analysis of in vivo studies showing curcumin's anti-proliferative effects via inhibition of oxidative stress and angiogenesis, and induction of apoptosis.
• Examination of clinical trials investigating curcumin's therapeutic potential and bioavailability enhancement.

Main Results:

• Curcumin exhibits potent cytotoxic and anti-proliferative effects against pancreatic cancer cells in vitro and in vivo.
• Mechanisms include modulation of molecular targets, inhibition of oxidative stress and angiogenesis, and induction of apoptosis.
• Clinical studies are exploring novel formulations to improve curcumin's bioavailability and therapeutic efficacy.

Conclusions:

• Curcumin demonstrates significant anticancer potential for pancreatic cancer, supported by preclinical evidence.
• Further clinical investigation, particularly with bioavailable formulations, is warranted to establish curcumin as a viable treatment option for advanced PC.
• Curcumin represents a promising natural compound for developing novel pancreatic cancer therapies.